文远知行-W(00800)发布公告，本公司目前设有一项股份计划，即2018年股份计划。2018年股份计划的 条款不符合《上市规则》第十七章的规定，因此，本公司于上市后不得根据2018年股份计划作出进一步 授予。因此，董事会建议采纳2026年股份计划，该计划的条款符合《上市规则》第十七章的规定。2026 年股份计划旨在透过授出奖励吸引、激励及留住雇员、董事及顾问。 2026年股份计划项下可予发行或转让的A类普通股(包括库存股份)之最高数目，不得超过本公司于股东 批准2026年股份计划之日已发行及发行在外股份总数(不包括任何库存股份)的10%(若发生任何股份拆 细、合并或类似交易，则将予以公平调整，以使该限额所占已发行及发行在外A类普通股的百分比于交 易前后维持不变)。在计划限额中，2026年股份计划项下可向顾问发行或转让的A类普通股(包括库存股 份)之最高数目，不得超过本公司于股东批准2026年股份计划之日已发行及发行在外股份总数(不包括任 何库存股份)的1%(若发生任何股份拆细、合并或类似交易，则将予以公平调整，以使该限额所占已发行 及发行在外A类普通股的百分比于交易前后维持不变)。 ...

2026年股份计划项下可予发行或转让的A类普通股(包括库存股份)之最高数目，不得超过本公司于股东 批准2026年股份计划之日已发行及发行在外股份总数(不包括任何库存股份)的10%(若发生任何股份拆 细、合并或类似交易，则将予以公平调整，以使该限额所占已发行及发行在外A类普通股的百分比于交 易前后维持不变)。在计划限额中，2026年股份计划项下可向顾问发行或转让的A类普通股(包括库存股 份)之最高数目，不得超过本公司于股东批准2026年股份计划之日已发行及发行在外股份总数(不包括任 何库存股份)的1%(若发生任何股份拆细、合并或类似交易，则将予以公平调整，以使该限额所占已发行 及发行在外A类普通股的百分比于交易前后维持不变)。 智通财经APP讯，文远知行-W(00800)发布公告，本公司目前设有一项股份计划，即2018年股份计划。 2018年股份计划的条款不符合《上市规则》第十七章的规定，因此，本公司于上市后不得根据2018年股 份计划作出进一步授予。因此，董事会建议采纳2026年股份计划，该计划的条款符合《上市规则》第十 七章的规定。2026年股份计划旨在透过授出奖励吸引、激励及留住雇员、董事及顾问。 ...

Group 1 - The core point of the announcement is that Tian Ge Interactive (01980) clarifies the status of 500,000 shares held by Xinshow Limited, which will be used to satisfy unvested share awards for an employee under the 2024 share plan [1] - As of the announcement date, the offeror has received 9 valid acceptances for a total of 121 million offer shares, representing approximately 10.92% of the company's total issued share capital [1] - The public shareholders collectively hold 231 million shares, accounting for about 20.85% of the total issued share capital, which is below the minimum public float requirement of 25% as per listing rules [1] Group 2 - The company has applied to the Stock Exchange for a waiver from strict compliance with the public float requirement for a period of five months, from January 8, 2026, to June 8, 2026 [2] - To restore the public float, the company plans to issue new shares under a general mandate at the upcoming annual general meeting on June 20, 2025, and grant awards to certain employee participants under the 2024 share plan [2] - The company may also communicate with its major shareholders to explore their willingness to reduce their holdings to meet the public float obligation [2]

Core Viewpoint - The company, Pony.ai-W (02026.HK), has proposed to adopt a new share plan for 2026, indicating a strategic shift in its equity compensation approach as it will not grant further awards under the 2016 share plan after its listing [1] Group 1 - The board of directors has resolved to recommend the adoption of the 2026 share plan on January 23, 2026 [1] - The company currently has no other outstanding share plans apart from the 2016 share plan [1] - The company will conditionally grant a total of 2 million restricted share units to key executives, including the chairman and CEO, Peng Jun, and the CTO, Lou Tiancheng, under the new 2026 share plan [1]

Core Viewpoint - The company Ensign Bio-B (09606) announced a proposed 2025 Share Plan aimed at attracting and retaining key contributors to its long-term development, pending shareholder approval [1] Group 1: 2025 Share Plan Objectives - The 2025 Share Plan is designed to recognize and reward participants for their past contributions to the company [1] - It aims to provide participants with opportunities to acquire proprietary rights of the company, encouraging further contributions to enhance the company's value [1] - The plan offers a flexible approach for the company to retain, incentivize, reward, and compensate participants, as well as provide benefits [1]

Core Viewpoint - The company announced a proposed 2025 Share Plan aimed at attracting and retaining key contributors to its long-term development and success, pending shareholder approval [1] Group 1 - The 2025 Share Plan is designed to recognize and reward participants for their past contributions to the company [1] - The plan will provide participants with opportunities to acquire proprietary rights of the company, encouraging further contributions to enhance the company's value [1] - The 2025 Share Plan offers a flexible approach for the company to retain, motivate, reward, and compensate participants, as well as provide benefits to them [1]

Core Viewpoint - China Health Technology Group (01069) announced a board resolution to propose a share plan, pending shareholder approval, aimed at aligning the long-term interests of its directors and key employees with the company's interests and incentivizing them to continue driving the company's growth and development [1] Group 1 - The proposed share plan is intended to enhance alignment between the interests of the company's leadership and the overall company objectives [1] - The plan is designed to motivate directors and key employees to contribute to the company's ongoing growth and development [1] - The implementation of the share plan is contingent upon approval from the shareholders [1]

Core Viewpoint - China Health Technology Group (01069.HK) announced a proposal for a share scheme aimed at aligning the long-term interests of its directors and key employees with the company's interests, thereby incentivizing them to drive the company's growth and development [1] Group 1 - The share scheme is set to be adopted on December 9, 2025, pending shareholder approval [1] - The implementation of the share scheme requires approval through an ordinary resolution at the annual general meeting and subsequent approval from the Stock Exchange of Hong Kong for the new shares to be issued under the scheme [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 SITC International Holdings Company Limited 1308 (1)截至二零二五年九月三十日止九個月的未經審核經營數據 及 (2)有關二零二四年年報的補充公告 截至二零二五年九月三十日止九個月的未經審核經營數據 於年報日期，根據股份計劃可發行的股份總數為264,347,788股，相當於本公 司於該日期已發行股本約9.84%。 承董事會命 海豐國際控股有限公司 海豐國際控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」）謹此公佈本集團截至二零二五年九月三十日止九個月的若干 未經審核經營數據及二零二四年同期的比較數字。 本集團的收入由截至二零二四年九月三十日止九個月的約2,108.5百萬美元增加 約16.6%至截至二零二五年九月三十日止九個月的約2,458.9百萬美元。截至二 零二五年九月三十日止九個月，本集團的集裝箱運量為2,749 ...

Group 1 - The core point of the article is that Jinxin Reproductive Medicine (01951) has proposed a 2025 Share Option Plan, which aims to align the long-term interests of the company's directors and key employees with those of the company, thereby incentivizing them to drive growth and development [1] - The 2025 Share Option Plan will constitute a share option scheme funded through the issuance of new shares, in accordance with Chapter 17 of the Listing Rules [1] - On September 25, 2025, the board resolved to grant a total of 137,235,000 share options to the management under the 2025 Share Option Plan, subject to conditional approval from independent shareholders at a special general meeting [1] Group 2 - Additionally, the board plans to grant a total of 2,400,000 share options and 1,200,000 restricted shares to non-executive participants under the 2025 Share Option Plan [1]